In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer

Promoter hypermethylation is central in deregulating gene expression in cancer. Identification of novel methylation targets in specific cancers provides a basis for their use as biomarkers of disease occurrence and progression. We developed an in silico strategy to globally identify potential targets of promoter hypermethylation in prostate cancer by screening for 5′ CpG islands in 631 genes that were reported as downregulated in prostate cancer. A virtual archive of 338 potential targets of methylation was produced. One candidate, IGFBP3, was selected for investigation, along with glutathione-S-transferase pi (GSTP1), a well-known methylation target in prostate cancer. Methylation of IGFBP3 was detected by quantitative methylation-specific PCR in 49/79 primary prostate adenocarcinoma and 7/14 adjacent preinvasive high-grade prostatic intraepithelial neoplasia, but in only 5/37 benign prostatic hyperplasia (P<0.0001) and in 0/39 histologically normal adjacent prostate tissue, which implies that methylation of IGFBP3 may be involved in the early stages of prostate cancer development. Hypermethylation of IGFBP3 was only detected in samples that also demonstrated methylation of GSTP1 and was also correlated with Gleason score ⩾7 (P=0.01), indicating that it has potential as a prognostic marker. In addition, pharmacological demethylation induced strong expression of IGFBP3 in LNCaP prostate cancer cells. Our concept of a methylation candidate gene bank was successful in identifying a novel target of frequent hypermethylation in early-stage prostate cancer. Evaluation of further relevant genes could contribute towards a methylation signature of this disease.

[1]  C. Sawyers,et al.  In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). , 2001, Cancer research.

[2]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[3]  Yusuke Nakamura,et al.  Molecular Features of the Transition from Prostatic Intraepithelial Neoplasia (PIN) to Prostate Cancer , 2004, Cancer Research.

[4]  F. Khuri,et al.  Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer , 2004, Oncogene.

[5]  K. A. Walker,et al.  Epigenetic Gene Inactivation Induced by a Cis-acting Methylation Center (*) , 1995, The Journal of Biological Chemistry.

[6]  H. Shiraha,et al.  Functional promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor specific methylation , 2005, BMC Cancer.

[7]  E Mahlamäki,et al.  Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. , 1999, Journal of the National Cancer Institute.

[8]  Hyeon Joo Lee,et al.  Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia , 2004, The Journal of pathology.

[9]  Daiya Takai,et al.  Comprehensive analysis of CpG islands in human chromosomes 21 and 22 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Katsaros,et al.  Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential , 2006, Cancer.

[11]  A. Perry,et al.  The emerging roles of DNA methylation in the clinical management of prostate cancer. , 2006, Endocrine-related cancer.

[12]  M. Hoque,et al.  A Quantitative Promoter Methylation Profile of Prostate Cancer , 2004, Clinical Cancer Research.

[13]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[14]  Jeanne Kowalski,et al.  Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer , 2004, Cancer Research.

[15]  M. Grzmil,et al.  cDNA microarray analysis with amplified RNA after isolation of intact cellular RNA from neoplastic and non-neoplastic prostate tissue separated by laser microdissections. , 2004, International journal of oncology.

[16]  Stephen B. Baylin,et al.  Mapping Patterns of CpG Island Methylation in Normal and Neoplastic Cells Implicates Both Upstream and Downstream Regions inde Novo Methylation* , 1997, The Journal of Biological Chemistry.

[17]  J. Thrasher,et al.  Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: clinical correlations. , 1996, The Journal of urology.

[18]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[19]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[20]  Tom H. Pringle,et al.  The human genome browser at UCSC. , 2002, Genome research.

[21]  M. Kattan,et al.  Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study. , 1998, The Journal of urology.

[22]  David Handelsman,et al.  Identification of differentially expressed genes in organ‐confined prostate cancer by gene expression array , 2001, The Prostate.

[23]  Li Mao,et al.  Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  M. Uemura,et al.  Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. , 2002, Cancer letters.

[25]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[26]  A. Papatsoris,et al.  Novel insights into the implication of the IGF-1 network in prostate cancer. , 2005, Trends in molecular medicine.

[27]  D. S. Prestridge.  Predicting Pol II promoter sequences using transcription factor binding sites. , 1995, Journal of molecular biology.

[28]  K. Miller,et al.  Regularly methylated novel pro‐apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder , 2006, International journal of cancer.

[29]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[30]  L. Giudice,et al.  Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. , 1992, The Journal of clinical endocrinology and metabolism.

[31]  D. Lancet,et al.  GeneCards: integrating information about genes, proteins and diseases. , 1997, Trends in genetics : TIG.

[32]  M. Matsuoka,et al.  Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia. , 2000, Cancer research.

[33]  J. Hicks,et al.  Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. , 2003, The American journal of pathology.

[34]  D. Sidransky,et al.  Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. , 2001, Journal of the National Cancer Institute.

[35]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[36]  Hiroyuki Takahashi,et al.  Altered methylation of multiple genes in carcinogenesis of the prostate , 2003, International journal of cancer.

[37]  P. Laird,et al.  MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.

[38]  Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice. , 2001, Endocrinology.

[39]  S. Plymate,et al.  Insulin‐like growth factor binding protein‐3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo , 2002, The Prostate.

[40]  Yong Wang,et al.  An evaluation of new criteria for CpG islands in the human genome as gene markers , 2004, Bioinform..

[41]  J. Welsh,et al.  Molecular classification of human carcinomas by use of gene expression signatures. , 2001, Cancer research.

[42]  A. Carvalho,et al.  Epigenetic Heterogeneity of High-Grade Prostatic Intraepithelial Neoplasia: Clues for Clonal Progression in Prostate Carcinogenesis , 2006, Molecular Cancer Research.

[43]  R. Rosenfeld,et al.  Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. , 1993, The Journal of biological chemistry.